Abstract
Although genome mining has advanced the identification, discovery, and study of microbial natural products, the discovery of bacterial diterpenoids continues to lag behind. Herein, we report the identification of 66 putative producers of novel bacterial diterpenoids, and the discovery of the tiancilactone (TNL) family of antibiotics, by genome mining of type II diterpene synthases that do not possess the canonical DXDD motif. The TNLs, which are broad-spectrum antibiotics with moderate activities, are produced by both Streptomyces sp. CB03234 and Streptomyces sp. CB03238 and feature a highly functionalized diterpenoid skeleton that is further decorated with chloroan-thranilate and γ-butyrolactone moieties. Genetic manipulation of the tnl gene cluster resulted in TNL congeners, which provided insights into their biosynthesis and structure–activity relationships. This work highlights the biosynthetic potential that bacteria possess to produce diterpenoids and should inspire continued efforts to discover terpenoid natural products from bacteria.
Keywords: antibiotics, biosynthesis, terpenoids, genomics, natural products
Terpenoids are the largest, most structurally diverse family of natural products with over 70000 known compounds (http://dnp.chemnetbase.com). Terpenoids of bacterial origin, however, are relatively rare, with diterpenoids epitomizing this disparity.[1] Although recent genomics, bioinformatics, and experimental studies support that terpene synthases (TSs) are widely distributed in bacteria,[2] only a handful of highly functionalized bacterial diterpenoids are known. The structures and gene clusters of platensimycin (PTM) and platencin (PTN),[3] the gibberellins,[4] phenalinolactone (PLA),[5] and brasilicardin (BRA)[6] exemplify the biosynthetic potential of bacteria to produce unique, biologically active, diterpenoid natural products (Scheme 1 and Figure S1 in the Supporting Information).
The genomic era has seen a rejuvenation in the discovery of natural products. Genome mining for novel natural products is prevalent among polyketides,[7] nonribosomal peptides,[8] hybrid polyketide–nonribosomal peptides,[9] and ribosomally synthesized and post-translationally modified peptides,[10] Yet, the discrepancy in numbers of diterpenoids found in plants and fungi versus bacteria suggests inefficient means for diterpenoid discovery in bacteria. Given that bacteria indeed possess the biosynthetic machinery needed for diterpenoid production,[1, 11] genome mining for complex diterpenoid natural products should be achievable.
TSs utilize carbocation chemistry to catalyze their diverse cyclization reactions and are divided into two subtypes,[11, 12] Type I TSs catalyze the heterolytic cleavage of the diphosphate moiety, that is, ionization, on the prenyl diphosphate substrate; type II TSs protonate a double bond or epoxide, that is, protonation, while leaving the diphosphate moiety intact (Figure S2). Canonical types I and II TSs possess signature sequence motifs, DDxxD and NSE/DTE, and DxDD, respectively, that are associated with initial carbocation formation and have been utilized as probes to identify uncharacterized TSs.[11] Diterpene synthases (DTSs) with atypical sequence motifs are known, but rare, with the type I ent-atiserene synthase PtmT1/PtnT1 (two DxxxD motifs) from PTN biosynthesis[3b] and the type II DTSs PlaT2 (DSAN) and Bra4 (ESAE) from PLA and BRA biosynthesis, respectively, as examples.[5a, 6b] The atypical sequence motifs of PlaT2 and Bra4 suggest that they protonate an epoxide, resembling the eukaryotic tri-TS oxidosqualene cyclase (OSC; Figure S2).[13]
We targeted gene clusters containing genes that encoded atypical type II DTSs. A sequence similarity network (SSN) of type II TSs, built from the Structure-Function Linkage Database at UCSF,[14] revealed that known type II DTSs only populated four small clusters at an e value of 10−5 (Figure 1A). The largest cluster contains canonical DTSs from actinobacteria, including, but not limited to, the copalyl diphosphate synthases PtmT2 and CPS, the terpentedienyl diphosphate synthase CYC1, and the labdadienyl diphosphate synthase SCLAV_ p0490.[15] The three smaller clusters contain the atypical DTSs, including PlaT2 and Bra4,[5a, 6b] BjCPS from the proteobacterium Bradyrhizobium japonicum, and halimadienyl diphosphate synthase Rv3377c from Mycobacterium tuberculosis.[16] Interestingly, Lon15, a tetra-TS involved in longestin (LON) biosynthesis/[17] clusters together with PlaT2 and Bra4. Although tetra-TS Lon15 is included in this subfamily, for simplicity, we use term “DTS” to refer to the subfamily or members therein.
An SSN of PlaT2/Bra4-like DTSs was constructed to differentiate these atypical type II DTSs.[18] This network, which consists of 66 unique homologues from actinobacteria (Table S1), is comprised of three major subfamilies at an e value of 10−142: 44 Bra4-like proteins, 12 PlaT2-like proteins, and six Lon15-like proteins (Figure 1B). Three of these DTSs were from strains in the Actinomycetales strain collection at The Scripps Research Institute. Two DTSs, TnlT2 from CB03234 and CB03238,[7a, 19] clustered with PlaT2; the third, from Micromonospora sp. TSRI0369,[7a] clustered with Bra4 (Figure 1B). At a threshold of 10−158, Bra4 separates from a cluster that mainly consists of DTSs from Micromonospora spp. (Figure 1B). A phylogenetic tree of these 66 DTSs supports the SSN subfamilies (Figure S3). None of these DTSs contain the canonical type II DxDD motif, or retain the central Asp as in OSCs;[12] instead, they possess a consensus motif of (E/D)(T/S)xE, in which x is an aliphatic amino acid (Figures 1C and S4). A genome neighborhood network (GNN) of the 66 DTSs was constructed to differentiate, annotate, and prioritize the gene clusters for natural-product discovery (Figures S5 and S6).[20] By using a neighborhood size of 20 genes (41 total genes per DTS) and an e value of 10−5, 60 of the 66 type II DTS-encoding genes are in genetic proximity to genes that encode a polyprenyl diphosphate epoxidase and a UbiA-like prenyltransferase (Table S1). These two proteins were previously predicted to epoxidize the terminal double bond on the polyprenyl diphosphate and catalyze a type I TSs-like extension of the terpene scaffold, respectively.[5a, 6b] Furthermore, 59 of these 60 gene clusters also encode at least one polyprenyl synthase (Table S1). Together, these four core genes represent the genetic foundation for this family of bacterial diterpenoids. Gene clusters that do not contain all four genes have homologues elsewhere in the genome, although it is unclear if they are involved in the biosynthesis of these natural products (Table S2). In addition, significant numbers of diverse tailoring enzymes encoded by genes in proximity to these core genes indicate that the nascent terpenoid skeletons undergo extensive modifications to afford structural diversity in this family of natural products.
We prioritized CB03234 and CB03238 for diterpenoid discovery based on 1) their presence in our Actinomycetales strain collection (Figure S7); 2) differences in the gene clusters for tiancilactone (TNL), PLA, BRA, and LON (Scheme 1B, Figure S5, and Tables S3–S6); and 3) the fact that CB03234 is genetically amenable.[7a] We first generated the ΔtnlT2 mutant strain SB23001 from CB03234 (Tables S7–S9 and Figure S8).[21] Both CB03234 and CB03238 wild-type (WT) strains were then fermented under conditions known for diterpenoid production,[22] with SB23001 as a negative control. HPLC analysis revealed three distinct metabolites from the CB03234 and CB03238 WT strains that were abolished in SB23001 (Figure 2A); this confirmed that they were encoded by the tnl and tnl’ gene clusters. A large scale (24 L) fermentation of CB03234 was then performed, which resulted in the isolation of eight natural products, TNLs A–H (1–8; Figure 2B). The structures of 1–8 (Scheme 2A) were determined based on a combination of high-resolution ESIMS (HRESIMS), 1D and 2D NMR spectroscopy, chemical transformation, and computational methods (Tables S10–S12 and Figures S9–S71).
TNL A (1), the major product of CB03234, had a molecular formula of C32H44ClNO8 based on HRMS (ESI) analysis (m/z 606.2836 [M+H]+; Figure S9) and the 3:1 ratio of the peak heights for a Cl-containing natural product (Figure S10). The NMR spectra (Table S10) of 1 showed resonances that were consistent with those of PLA CD2, with two key differences (Figure S1).[5a] The C-12—C-13 double bond in PLA CD2 was lost and the C-12 position in 1 was oxygenated, as supported by the 1H NMR doublet of CH3-16 and HMBC correlations of CH3-16 with C-12 and C-13 (Scheme 2B). The second difference was the moiety attached at C-18. The low-field signals of δH = 7.79 (d), 7.31 (dd), and 6.68 ppm (d) suggested the presence of a 2,4,5-trisubstituted benzoate moiety. In addition, HMBC correlations of H-3’ with C-1’, C-2’, C-4’, and C-7’ suggested that this 2,4,5-trisubstituted benzoate was a C-4’-chloroanthranilate (Scheme 2A and B).
The structures of 2–7 were similarly elucidated (see the Supporting Information). TNL B (2) was the deschloro congener of 1; TNL C (3) possessed the chloroanthranilate moiety on C-3 instead of C-18; TNLs D (4) and E (5) had modified γ-butyrolactone moieties; TNL F (6) lost a carboxyl group on the γ-butyrolactone moiety of 1, which resulted in a malondialdehyde side chain; TNL G (7) had the γ-butyrolactone moiety of 1 replaced by an ethanol tail; and TNL H (8), which was not oxidized at C-18 or C-12 and did not possess the chloroanthranilate and γ-butyrolactone moieties, was an ether-containing (C-11 and C-15) diterpenoid skeleton with a carboxylic acid side chain (Scheme 2A).
The relative stereochemistry of 1 was elucidated by analysis of the ROESY spectra. Correlations between H-3 and H-1b, H-3 and H-5, H-5 and H-9, H-9 and CH3-17, and CH3-20 and CH3-19 established the 3S*, 4R*, 5R*, 8S*, 9R*, and 10R* configurations (Scheme 2B), the result of which was an anti/anti/syn-perhy-drophenanthrene scaffold. The key ROESY correlations between CH3-20 and H-12, and H-12 and H-14, along with a correlation between H-13 and CH3-17, established the 12S*, 13R*, and 14S* configurations (Scheme 2B). Because each of these key ROESY correlations was also detected in 2–7, their relative stereochemistries were assigned to be the same as that of 1.
Based on the ROESY correlations observed, the stereochemistries of C-3, C-5, C-8, C-9, and C-10 in 8 are identical to those in 1 (Scheme 2C). Furthermore, ROESY correlations between H-12 and CH3-20, together with correlations between H-15 and CH3-17, and H-15 and H-9, supported the 11R* and 15S* configurations of 8. The absolute stereochemistry of C-3 was determined to be S by means of the modified Mosher method (Scheme 2C and Figures S68–S71).[23] Taken together, the absolute stereochemistry of 8, and thus, the TNLs, was established (Scheme 2A). This assignment was further supported by density functional theory calculations with the optical rotation (OR) of 8 (see the Supporting Information): experimental, −108.3°; calculated, −128.2°.
Using the GNN, we predicted the genetic boundaries of the tnl gene cluster and generated the Δtnlorf1 and Δtnlorf3 mutant strains SB23002 and SB23003, respectively, from CB03234 (Figures S5, S72, and S73).[21] Fermentation of SB23002 and SB23003 revealed that neither mutation affected TNL production (Figure S74); this confirmed that orf1 and orf3 were not required for TNL biosynthesis. We also inactivated two methyltransferase-encoding genes, tnlM1 and tnlP5, which resulted in mutant strains SB23004 and SB23005, respectively (Tables S7–S9 and Figures S75 and S76). Fermentation of SB23004 and SB23005 resulted in the accumulation of three new metabolites, TNLs I (9), J (10), and K (11; Scheme 2A, Figures 2A, and S77–S97, as well as Table S13). The disappearance of the CH3-24 signal and an upfield migration of the chemical shift of C-12 in 9 supported the structure of 9 and the function of TnlM1 as an O-methyltransferase. Supported by a new signal at δC = 216.5 ppm and a molecular weight 2 Da less than that of 9, the structure of 10 had a ketone at C-12. TNL K (11), clearly lost the signal of CH3-8’ (δH = 2.86 ppm) in 1, which confirmed the demethylated structure of 11 and TnlP5 as an N-methyltransferase.
The discovery of the TNLs and genetic studies of the tnl gene cluster, along with previous studies on the PLA and BRA biosynthetic pathways,[5a, b, 6b, c] provides a logical biosynthetic pathway for the TNLs (Scheme 3). After geranylgeranyl diphosphate (GGPP) is biosynthesized and terminally epoxidized by TnlT4 and TnlT1, respectively, TnlT2 catalyzes the cyclization of epoxyGGPP to form a (3S)-hydroxydodecahydrophenanthrene scaffold, which presumably retains the diphosphate group at C-15. TnlT3 then catalyzes a prenylation-like addition of three carbon atoms to the C-15 carbocation, possibly in the form of phosphoenolpyruvate;[5a] these four carbon atoms eventually form the γ-butyrolactone moiety. Based on the isolation of PLA CD6, which contains an enone in the C-15 side chain (Figure S1),[5a] TNL is likely to undergo a similar oxidation prior to C-21 hydroxylation and γ-butyrolactone formation by TnlO1 (Scheme 3A). The intermediacy of this oxidized 23-carbon scaffold is supported by the structure of 8, which is a decarboxylated and C-11 oxidized (the ether might arise from a nonenzymatic oxo-Michael addition) shunt product that retains the C-12—C-13 double bond and unoxidized C-18 methyl group (Scheme 2A). The enzyme responsible for desaturation at C-15—C-21 is still unknown given that the previously proposed dehydrogenase in PLA biosynthesis, PlaZ,[5a] is not conserved in the TNL gene clusters.
Four tailoring steps complete the biosynthesis of 1 (Scheme 3). Hydroxylation at C-18 and C-12 is required prior to acylation and methylation. Based on analysis by using a cytochrome P450 SSN from Streptomyces (Figure S98),[25] these hydroxylations are expected to be catalyzed by the TnlO4 and TnlO3 P450s, respectively; sequence similarities between PlaO2 and TnlO2 and the lack of a third, clear P450 transformation suggest that TnlO2 may be nonfunctional.[5b] Based on the presence of genes encoding the tryptophan dioxygenase TnlP2 and tryptophan halogenase TnlP3, and the isolation of the deschloro congener 2, the chloroanthranilate moiety is derived from tryptophan via (chloro)kynurenine. Chloroanthranilate is first activated by the adenosine triphosphate (ATP)-dependent synthetase TnlP4, which is transferred to the peptidyl carrier protein TnlP1, and finally transferred to the C-18 hydroxy group. C-18 acylation is likely to be catalyzed by TnlP6 (Scheme 3B), based on its similarity to the acyltransferase CloN7 from clorobiocin biosynthesis.[26] N-Methylation on the anthranilate moiety is catalyzed by TnlP5; however, it is unclear if this occurs prior to or after anthranilate installation given that desmethyl congener 11 has no other structural changes, relative to 1 (Scheme 2A). Finally, O-methylation, which is catalyzed by TnlM1 and supported by the isolation of 9, completes the biosynthesis of 1 (Scheme 3). The C-12 oxo moiety of 10 is likely to result from extraneous oxidation of the C-12 hydroxy group. TNLs C-G (3–7) are presumably shunt products or isolation artifacts that are either the result of nonenzymatic transformations, that is, 3–5, or degradation of the γ-butyrolactone moiety, that is, 6 and 7.
The TNLs showed moderate broad-spectrum antibacterial activities. A disk diffusion assay showed clear inhibition zones for 1 and 3–5 against Staphylococcus aureus, Kocuria rhizophila, Mycobacterium smegmatis, and Pseudomonas putida (Figure S99). Inhibition zones were also found for 1 and 3–5 against Bacillus subtilis and Escherichia coli, but were not as clear. Minimum inhibitory concentrations (MICs) of TNLs 1–5 and 8 were determined by using the broth dilution method.[24] Although none of the compounds showed activity against B. subtilis or E. coli (i.e., MIC> 64 μgmL−1), TNLs A–E (1–5) exhibited MICs ranging from 8–64 μgmL−1 against S. aureus, K. rhizophila, M. smegmatis, and P. putida (Table S14). Due to limited quantities, TNLs F (6) and G (7) were not tested. No inhibition zones were found for 9–11 against any of the tested strains, which suggested that the C-12 methoxy group and/or the N-methyl group of the chloroanthranilate moiety were indispensable for antibiotic activity. In comparison, the PLAs exhibited MIC values of 3–30 μgmL−1 against Gram-positive bacteria, but had no activity against Gram-negative strains;[5c] BRA showed no antibacterial activity.[6a]
In summary, we identified a family of 66 putative diterpenoid gene clusters, 63 of which were new, by searching for gene clusters that encoded type II DTSs without the canonical DxDD motif. This study challenges the current paradigm of the rarity of terpenoids in bacteria, and provides an extraordinary opportunity to discover and study new biosynthetic pathways that result in highly functionalized bacterial terpenoids. The unique structures of the TNLs, composed of a diterpene-derived anti/anti/syn-perhydrophenanthrene skeleton attached to γ-butryolactone and chloroanthranilate moieties, support future screening efforts of these diterpenoids against an array of biological targets. Furthermore, differences in the activities of the TNLs, PLAs, and BRA suggest distinct modes of action. The anti/anti/syn and anti/syn/anti configurations of the tricyclic cores in TNL and BRA implicate that the DTSs or polyprenyl epoxidases in these gene clusters do not all generate identical stereoisomers (Figures S3 and S100); this further expands the potential for structural diversity. Finally, although canonical enzymes, domains, or motifs are typically used in genome mining, the discovery of the TNLs by identifying biosynthetic machineries with atypical motifs is applicable to all classes of natural products.
Supplementary Material
Acknowledgements
This work is supported, in part, by National Institutes of Health grant GM114353 (to B.S.). J.D.R. is supported, in part, by a National Institutes of Health Pathway to Independence Award GM124461. M.-R.D. is supported, in part, by the Guangdong Institute of Microbiology, Guangzhou, Guangdong, P.R. China, and a scholarship (2017GDASCX-0502) from the Guangdong Academy of Science, Guangzhou, Guangdong, P.R. China. We thank Dr. Qin-Shi Zhao from the Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan, P.R. China, for access to Discovery Studio. We thank the High Performance Computing Core at The Scripps Research Institute for providing HPC resources. This is manuscript #29668 from The Scripps Research Institute.
Footnotes
Conflict of Interest
The authors declare no conflict of interest.
References
- [1].Smanski MJ, Peterson RM, Huang S-X, Shen B, Curr. Opin. Chem. Biol 2012, 16, 132–141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [2].Yamada Y, Kuzuyama T, Komatsu M, Shin-ya K, Omura S, Cane DE, Ikeda H, Proc. Natl. Acad. Sci. USA 2015, 112, 857–862. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].a) Rudolf JD, Dong L-B, Shen B, Biochem. Pharmacol 2017, 133, 139–151; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Smanski MJ, Yu Z, Casper J, Lin S, Peterson RM, Chen Y, Wendt-Pienkowski E, Rajski SR, Shen B, Proc. Natl. Acad. Sci. USA 2011, 108, 13498–13503. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [4].Hedden P, Sponsel V, J. Plant Growth Regul. J. 2015, 34, 740–760. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5].a) Dürr C, Schnell H-J, Luzhetskyy A, Murillo R, Weber M, Welzel K, Vente A, Bechthold A, Chem. Biol 2006, 13, 365–377; [DOI] [PubMed] [Google Scholar]; b) Daum M, Schnell H-J, Herrmann S, Guenther A, Murillo R, Mueller R, Bisel P, Mueller M, Bechthold A, ChemBioChem 2010, 11, 1383–1391; [DOI] [PubMed] [Google Scholar]; c) Gebhardt K, Meyer SW, Schinko J, Bringmann G, Zeeck A, Fiedler H-P, J. Antibiot 2011, 64, 229–232. [DOI] [PubMed] [Google Scholar]
- [6].a) Komaki H, Nemoto A, Tanaka Y, Takagi H, Yazawa K, Mikami Y, Shigemori H, Kobayashi J. i., Ando A, Nagata Y, J. Antibiot 1999, 52, 13–19; [DOI] [PubMed] [Google Scholar]; b) Hayashi Y, Matsuura N, Toshima H, Itoh N, Ishikawa J, Mikami Y, Dairi T, J. Antibiot 2008, 61, 164–174; [DOI] [PubMed] [Google Scholar]; c) Schwarz PN, Roller L, Kulik A, Wohlleben W, Stegmann E, Buchmann A, Gross H, Gross H, Wohlleben W, Stegmann E, Biotechnol. J 2018, 13, 1700527. [DOI] [PubMed] [Google Scholar]
- [7].a) Yan X, Ge H, Huang T, Hindra, Yang D, Teng Q, Crnovcic I, Li X, Rudolf J, R. D, Lohman J, Gansemans Y, Zhu X, Huang Y, Zhao L-X, Jiang Y, Van Nieuwerburgh F, Rader C, Duan Y, Shen B, mBio 2016, 7, e02104–16; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Helfrich EJN, Reiter S, Piel J, Curr. Opin. Biotechnol 2014, 29, 107–115; [DOI] [PubMed] [Google Scholar]; c) Boddy CN, J. Ind. Microbiol. Biotechnol 2014, 41, 443–450. [DOI] [PubMed] [Google Scholar]
- [8].Baltz RH, J. Ind. Microbiol. Biotechnol 2018, https://doi.org/10.1007/s10295-017-1999-8. [Google Scholar]
- [9].Pan G, Xu Z, Guo Z, Hindra, Ma M, Yang D, Zhou H, Gansemans Y, Zhu X, Huang Y, Zhao L-X, Jiang Y, Cheng J, Van Nieuwerburgh F, Suh J-W, Duan Y, Shen B, Proc. Natl. Acad. Sci. USA 2017, 114, E11131–E11140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [10].Hetrick KJ, van der Donk WA, Curr. Opin. Chem. Biol 2017, 38, 36–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [11].Dickschat JS, Nat. Prod. Rep 2016, 33, 87–110. [DOI] [PubMed] [Google Scholar]
- [12].Christianson DW, Chem. Rev 2006, 106, 3412–3442. [DOI] [PubMed] [Google Scholar]
- [13].Wendt KU, Schulz GE, Corey EJ, Liu DR, Angew. Chem. Int. Ed 2000, 39, 2812–2833; [PubMed] [Google Scholar]; Angew. Chem 2000, 112, 2930–2952. [Google Scholar]
- [14].Akiva E, Brown S, Almonacid DE, Barber II AE, Custer AF, Hicks MA, Huang CC, Lauck F, Mashiyama ST, Meng EC, Mischel D, Morris JH, Ojha S, Schnoes AM, Stryke D, Yunes JM, Ferrin TE, Holliday GL, Babbitt PC, Nucleic Acids Res. 2014, 42, D521–D530. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [15].a) Rudolf JD, Dong L-B, Cao H, Hatzos-Skintges C, Osipiuk J, Endres M, Chang C-Y, Ma M, Babnigg G, Joachimiak A, Phillips GN, Shen B, J. Am. Chem. Soc 2016, 138, 10905–10915; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Ikeda C, Hayashi Y, Itoh N, Seto H, Dairi T, J. Biochem 2007, 141, 37–45; [DOI] [PubMed] [Google Scholar]; c) Xu M, Hillwig ML, Lane AL, Tiernan MS, Moore BS, Peters RJ, J. Nat. Prod 2014, 77, 2144–2147; [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Hamano Y, Kuzuyama T, Itoh N, Furihata K, Seto H, Dairi T, J. Biol. Chem 2002, 277, 37098–37104; [DOI] [PubMed] [Google Scholar]; e) Yamada Y, Komatsu M, Ikeda H, J. Antibiot 2016, 69, 515–523. [DOI] [PubMed] [Google Scholar]
- [16].a) Morrone D, Chambers J, Lowry L, Kim G, Anterola A, Bender K, Peters RJ, FEBS Lett. 2009, 583, 475–480; [DOI] [PubMed] [Google Scholar]; b) Nakano C, Okamura T, Sato T, Dairi T, Hoshino T, Chem. Commun 2005, 1016–1018. [DOI] [PubMed] [Google Scholar]
- [17].Hayashi Y, Onaka H, Itoh N, Seto H, Dairi T, Biosci. Biotechnol. Biochem 2007, 71,3072–3081. [DOI] [PubMed] [Google Scholar]
- [18].Gerlt JA, Bouvier JT, Davidson DB, Imker HJ, Sadkhin B, Slater DR, Whalen KL, Biochim. Biophys. Acta Proteins Proteomics 2015, 1854, 1019–1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [19].Hindra D, Yang Q, Teng L-B, Dong I, Crnovcic T, Huang H, Ge B, Shen, Org. Lett 2017, 19, 1386–1389. [DOI] [PubMed] [Google Scholar]
- [20].Gerlt JA, Biochemistry 2017, 56, 4293–4308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [21].Gust B, Challis GL, Fowler K, Kieser T, Chater KF, Proc. Natl. Acad. Sci. USA 2003, 100, 1541–1546. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [22].Smanski MJ, Peterson RM, Rajski SR, Shen B, Antimicrob. Agents Chemother 2009, 53, 1299–1304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [23].Ohtani I, Kusumi T, Kashman Y, Kakisawa H, J. Am. Chem. Soc 1991, 113, 4092–4096. [Google Scholar]
- [24].Wiegand I, Hilpert K, Hancock REW, Nat. Protoc 2008, 3, 163–175. [DOI] [PubMed] [Google Scholar]
- [25].Rudolf JD, Chang C-Y, Ma M, Shen B, Nat. Prod. Rep 2017, 34, 1141–1172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [26].Anderle C, Alt S, Bringmann G, Gust B, Heide L, Arch. Microbiol 2007, 187, 227–237. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.